Phase II clinical experience with the proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphoma
収録刊行物
-
- Proc Am Soc Clin Oncol
-
Proc Am Soc Clin Oncol 22 2566-, 2003